Indeed, our studies show that several BTK inhibitors, including ibrutinib, AVL-292 (spebrutinib) and acalabrutinib, effectively inhibit breast cancer and prostate cancer cell growth (Kokabee et al., 2015; Wang et al., 2016). Here, BTK is linked to prostate cancer.